



ICBTRT 2025

in *Hokkaido, Japan*

24th International Conference on Brain Tumor Research and Therapy

Program


Date : **June 22 sun - 25 wed, 2025**

Venue : **The Windsor Hotel TOYA Resort & Spa**

Conference Chair : **Koichi Ichimura, MD, PhD**

Specially Appointed Professor

Department of Pathology, Kyorin University Faculty of Medicine



ICBTRT2025.umin.jp

Lake TOYA in Summer: Courtesy of Toyako Onsen Tourist Association

明日の しあわせに 化ける術。

人知れずこっそり、世界中の“すきま”に潜んでいる。
火薬の力を使って瞬時にエアバッグを膨らませたり、
電子機器の半導体に使われる樹脂をつくったり、
また、人々の健康を守る抗がん剤などの医薬品や
食料の安定供給に欠かせない農薬を提供していたり。
私たちは、技術をしあわせに化けさせる会社です。
現在から未来へ。すきまから世界へ。これからの
暮らしになくてはならない価値を、次々と発想します。

みてね!



世界的すきま発想。

 日本化薬





Invitation 3

Generous Support 4

Committees 6

Conference Information..... 7

Social Program 9

Instructions for Presentation..... 10


Exhibition..... 12

Room Location 13

Program at a Glance 14

Program..... 17

CONTENTS



Brain Tumor Center

The UCSF Health Brain Tumor Center offers leading clinical expertise, pioneering diagnostic and treatment advances and unparalleled support for patients, caregivers and families. Our world-class team of neurosurgeons, neuro-oncologists and neuroradiologists has extensive experience in treating specific tumor types using the latest approaches. By integrating research and clinical trials into every aspect of care, our center is at the forefront of pursuing novel ways to advance personalized therapies that optimize patient outcomes.



Conditions Treated

All types of benign and cancerous brain tumors, including:

- Gliomas
- Meningiomas
- Skull base tumors
- Neurofibromatosis type 1 (NF1) and related tumors
- Pituitary tumors
- Nerve and spine tumors

Brain Tumor Center

400 Parnassus Ave., Eighth Floor | San Francisco, CA 94143 | Phone: (415) 353-7500 Fax: (415) 353-2167

INVITATION

Message from the Conference Chair

Dear Friends and Colleagues,

It is our great honor and pleasure to welcome you to the 24th International Conference on Brain Tumor Research and Therapy (ICBTRT 2025).

ICBTRT is the most prestigious scientific conference that covers all aspects of brain tumor research, diagnosis and therapy. Since the first conference was held in 1975 in Asilomar, California, organized by Drs. Charlie Wilson, Takao Hoshino and Victor Levin from UCSF, the Conference is also known as 'Asilomar Meeting'. This year, we celebrate the 50-year anniversary of ICBTRT, marking its most significant milestone. The Conference is a great opportunity for the top neuro-oncology experts to meet and discuss the latest developments across diverse areas.

The Windsor Hotel TOYA Resort is a 5-star hotel situated by Lake Toya, a vast volcanic caldera lake, which is part of the Shikotsu-Toya National Park. The conference venue has a spectacular view of the volcanic lake and surrounding beautiful nature. They provide a secluded atmosphere that ensures a successful meeting and a pleasant stay.

We will make sure that the Conference is worth your trip all the way to Japan in these challenging times. We hope you will enjoy the Conference.

We look forward to welcoming you to TOYA!



A handwritten signature in black ink that reads "Koichi Ichimura". The signature is fluid and cursive, written on a light blue background.

Koichi Ichimura, M.D., Ph.D.

Conference Chair

The 24th International Conference on Brain Tumor Research and Therapy

Specially Appointed Professor

Department of Pathology

Kyorin University Faculty of Medicine

Generous Support

Seminars

Thank you to Our Sponsors

KONICA MINOLTA REALM, INC.



novocure®



S&Brain



varian
A Siemens Healthineers Company



Exhibitors

Baxter Japan K.K.
g.tec medical engineering GmbH
Novocure K.K.

S&Brain Corporation
ZAP Surgical Systems, Inc.
Nestle Healthscience Company

Donations

Arthur and Sonia Labatt Brain Tumour Research Centre
Hokuto Hospital / Hokuto Clinic
Saney Seiko Inc.

The Brain Tumour Charity
UCSF Department of Neurosurgery and the Brain Tumor Center
Yakukensha Co., Ltd.

Grant

The Uehara Memorial Foundation

Advertisement

10x Genomics Japan KK	MEDTRONIC JAPAN Co., Ltd.
Alfresa Pharma Corporation	Meiji Seika Pharma Co., Ltd.
Asahi Kasei Medical Co., Ltd.	Mizuho Urban Co., Ltd.
Bayer Yakuhin, Ltd.	NIHON SERVIER CO., LTD.
Carl Zeiss Meditec Co., Ltd.	Nippon Kayaku Co., Ltd.
CSL Behring K.K.	Ohwa Tsusho Co., Ltd.
Daiichi Sankyo Co., Ltd.	Ozakirika, Inc.
Eisai Co., Ltd.	Saney Seiko Inc.
Gunze Medical Limited	SBI Pharmaceuticals Co., Ltd.
IKEDA SCIENTIFIC Co., Ltd.	Sumitomo Pharma Co., Ltd.
INNOMEDICS Medical Instruments Inc.	Summit Pharmaceuticals International Corporation
Integra LifeSciences Holdings Corporation	Thermo Fisher Scientific K.K.
JOKOH CO., LTD.	UCB Japan Co. Ltd.
Leica Biosystems	

Homepage Banner

Illumina K.K.	Thermo Fisher Scientific K.K.
Keyence Corporation	

Neck Strap

The Brain Tumour Charity

(in alphabetical order)

日本製薬団体連合会寄付

(List of Sponsors through the Federation of Pharmaceutical Manufacturer's Association of JAPAN)

旭化成ファーマ(株)	キッセイ薬品工業(株)	第一三共(株)	日本臓器製薬(株)
あすか製薬(株)	クラシエ(株)	田辺三菱製薬(株)	ニプロファーマ(株)
アステラス製薬(株)	佐藤製薬(株)	中外製薬(株)	扶桑薬品工業(株)
アストラゼネカ(株)	参天製薬(株)	帝人ファーマ(株)	丸石製薬(株)
アルフレッサファーマ(株)	沢井製薬(株)	テルモ(株)	マルホ(株)
栄研化学(株)	(株)三和化学研究所	鳥居薬品(株)	(株)ミノファージェン製薬
エーザイ(株)	塩野義製薬(株)	東和薬品(株)	Meiji seika ファルマ(株)
小野薬品工業(株)	(株)ツムラ	トーアエイヨー(株)	持田製薬(株)
大塚製薬(株)	住友ファーマ(株)	日本ケミファ(株)	(株)ヤクルト本社
(株)大塚製薬工場	武田薬品工業(株)	日本たばこ産業(株)	ロート製薬(株)
科研製薬(株)	ゼリア新薬工業(株)	日本ベーリンガーインゲルハイム(株)	わかもと製薬(株)
杏林製薬(株)	大正製薬(株)	日本化薬(株)	
協和キリン(株)	大鵬薬品工業(株)	日本新薬(株)	

Committees

Conference Chair

Koichi Ichimura, M.D., Ph.D.

Specially Appointed Professor, Department of Pathology, Kyorin University Faculty of Medicine

Vice Chair

Ryo Nishikawa, M.D., Ph.D.

Emeritus Professor, Saitama Medical University, Director, Nerima-stn Rehabilitation Hospital

Yoshitaka Narita, M.D., Ph.D.

Chief, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital

Yoshiki Arakawa, M.D., Ph.D.

Professor and Chair, Department of Neurosurgery, Kyoto University Graduate School of Medicine

Secretary-General

Hirokazu Takami, M.D., Ph.D.

Lecturer, Department of Neurosurgery, The University of Tokyo

Steering Committee (alphabetical order)

David M Ashley

Duke University, USA

Mitchel S Berger

UCSF, USA

Rolf Bjerkvig

University of Bergen, Norway

Koichi Ichimura

Kyorin University, Japan

Ryo Nishikawa

Saitama Medical University, Japan

Russel Pieper

UCSF, USA

James Rutka

SickKids, Canada

John Sampson

Duke University, USA

Manfred Westphal

UKEppendorf, Germany

Local Organizing Committee

Koichi Ichimura

Kyorin University, Japan

Ryo Nishikawa

Saitama Medical University, Japan

Yoshitaka Narita

National Cancer Center Hospital, Japan

Yoshiki Arakawa

Kyoto University, Japan

Hirokazu Takami

The University of Tokyo, Japan

Secretariat of ICBTRT 2025

c/o Convex Inc.

BPR Place Kamiyacho, 1-11-9 Azabudai Minato-ku, Tokyo 106-0041 Japan

Tel: +81-3-3505-1600 Fax: +81-3-3505-3366

E-mail: icbtrt2025@convex.co.jp

Conference Information

I Date

June 22 (Sun) – 25 (Wed), 2025

I Venue

The Windsor Hotel TOYA Resort & Spa
 Shimizu, Toyako-cho, Abuta-gun, Hokkaido 049-5722 Japan
 Tel: +81-142-73-1111
 Website: <https://www.windsor-hotels.co.jp/en/>

I Registration Desk

The Registration Desk is located at the banquet lobby (outside The Windsor Hall D) and is open during the following hours:

June 22 (Sun) 13:00-18:00
 June 23 (Mon) 07:30-17:00
 June 24 (Tue) 07:45-13:00
 June 25 (Wed) 07:45-13:30

I Registration Fee (For on-site)

Category	Registration Fee
Delegates	JPY140,000
Accompanying Persons	JPY60,000

Note: The registration fees do not include accommodation, transportation, or accompanying persons' program.

I Registration Fee Includes:

For Delegates	For Accompanying Persons
● Attendance to all Scientific Sessions ● Program Book ● Access to Abstract ● Welcome Reception, Conference Dinner and Japan Night ● Excursion	● Welcome Reception, Conference Dinner and Japan Night ● Excursion

I Name Badge, Certificate and Program Book

You are requested to come to the Registration Desk to pick up your conference kit within the above time frame. The name badge is mandatory for access to all scientific sessions, the welcome reception, and exhibition room during the conference.

I Abstracts

All abstracts in the program will be available for download from our website. Please access the download file by using the password below. Scan the QR below to access e-Abstracts.

URL: <https://icbtrt2025.umin.jp/program/files/abstracts.pdf>

*Delegates will receive the password from the secretariat by email.



I Internet Access

Free WiFi is available in the whole building of Windsor Hotel TOYA Resort & Spa.

SSID: Windsor-Toya

Password: WHT202506

I Contact

c/o Convex Inc.

BPR Place Kamiyacho, 1-11-9 Azabudai Minato-ku, Tokyo 106-0041 Japan

TEL: +81-3-3505-1600 FAX: +81-3-3505-3366

E-mail: icbtrt2025@convex.co.jp

Social Program

I Welcome Reception

Date: June 22(Sun)

Time: 18:00-20:00

Place: The Windsor Hotel TOYA - Windsor Hall D

I Conference Dinner

Date: June 23(Mon)

Time: 18:00-18:30 Cocktail 18:30-20:30 Dinner

Place: The Windsor Hotel TOYA - Windsor Hall

I Japan Night

Date: June 24(Tue)

Time: 18:00-20:30

Place: The Windsor Hotel TOYA - Windsor Hall, Banquet Lobby & Garden

I Excursion

Date: June 24(Tue)

Time: 13:15-17:30

The excursion includes tours of Mt. Usu and Lake Toya (the main volcano and its caldera lake) in the Shikotsu-Toya National Park.

I Accompanying Persons' Program

※Registration fee not included

• Japanese Cooking Class and Tasting

Date: June 23(Mon)

Time: 11:00-13:00

Place: Restaurant La voûte in the Windsor Hotel 11F

Fee: JPY10,000

• Experiencing Hokkaido and Lunch

Date: June 24(Tue)

Time: 09:00-13:00

Place: Jam-making at a fruit orchard ⇒ BBQ course lunch by a private chef at

The Destination Lake Toya Garden Terrace ⇒ 13:00~ joining the excursion

Fee: JPY10,000

Instructions for Presentation

I Instructions for Moderators


1. Please come to your session 15 minutes before it starts. The seat for the next chairperson will be in the front middle row.
2. Please proceed with the session per the following time allocation.

I Instructions for Presentation

1. The time allotted for each presentation:
Please refer to the email from the ICBTRT 2025 Secretariat for your designated presentation time.
2. The time allotted for each presentation slot is scheduled as follows:

Presentation Slot (mins)	Presentation Time (mins)	Q&A Time (mins)
30	25	5
15	12	3
10	8	2
7	6	1
6	5	1
5	4	1

3. A green light on the podium will light up during your presentation.
4. A yellow light on the podium will tell you when one minute remains.
5. At the end of the allotted time for each presentation, a red light will tell you the time is over as well as a bell rings.
6. If the presenter continues to speak after the bell, a staff member will turn off the microphone after a further 30 seconds.
7. All presentations will be done on PC.
8. PCs with Windows and PowerPoint are able to be used onsite. Macintosh users: Please bring your own computer for your presentation.
9. Please bring your own PC or presentation data (PPT) saved in a storage device. Acceptable storage devices are CD-R and USB Flash memory only.
10. Audio, video, and animation are playable on the PCs used onsite. If you are bringing your presentation data in storage devices, please make sure that the data is compatible with Media Players for Windows.
11. Please use the following settings in PowerPoint for your presentation slides:
 - Standard PC fonts for Windows
 - 16:9 slide size
 - Refrain from using Presenter View
12. If you are using your own PC, please make sure to bring an AC adaptor (standard 2-pin type) to charge your PC. For projector output purposes, a VGA cable or HDMI cable will be provided. Please confirm whether your PC is equipped with a VGA port (mini D-sub 15 pin type) or HDMI port. If you use a different type of port to connect to an external monitor, please bring a converter with you. Please turn off your screen saver and power saving settings in advance, especially if your presentation includes video and sound.



13. Please bring your PC or data to the **PC Preview Desk** at least 30 minutes prior to your presentation to register and submit it to test the connection and view your file. **PC Review Desk:** It is located at the front of the conference room, in the foyer area outside The Windsor Hall A. It will be open during the following hours:
June 23 (Mon) 07:30-15:30
June 24 (Tue) 07:45-13:00
June 25 (Wed) 07:45-15:00
14. Please take your seat in the 'Next Speaker' area, located in the front row, at least 15 minutes before your scheduled presentation time.
15. Please use the mouse and PPT clicker on the podium for your presentation. You are required to handle your data by yourself, using the mouse and PPT clicker connected to the PC.
16. The copied data for your presentation will be deleted by the secretariat after the meeting.

Disclosure of Conflicts of Interest (COI)

Disclosure in slides

All presenters must declare their COI status on the first presentation slide (or immediately after the title and presenters) as shown in the example below.

e.g.1)

ICBTRT 2025 COI Declaration Affiliation Name (all presenters) The presenter has no conflict of interest with any corporate organizations relating to this presentation.
--

e.g.2)

ICBTRT 2025 COI Declaration Affiliation Name (all presenters) The presenter has potential conflicts of interest with the corporate organization below: Name of organizations
--

Exhibition


The exhibition is held in the foyer area outside The Windsor Hall and opens during the following hours:

- June 23 (Mon) 07:45-15:30
- June 24 (Tue) 08:00-13:00
- June 25 (Wed) 08:00-13:30

List of Exhibitors


No.	Exhibitors
1	Baxter Japan K.K.
2	g.tec medical engineering GmbH
3	S&Brain Corporation
4	Novocure K.K.
5	ZAP Surgical Systems, Inc.
6	Nestle Healthscience Company

Floor Plan




Room Location

1F North Wing



B1F South Wing



Program at a Glance

Day 1 (June 22)		Day 2 (June 23)			
Registration (Lobby)		Session Room 1 (Windsor Hall A-C)	Session Room 2 (Duke)	Exhibition/Registration (Lobby)	
8:00					Registration
		7:45~7:55 Opening remarks			
		8:00~8:30 Special Lecture 1 Moderator: Koichi Ichimura Lecturer: John R. Adler Sponsor: ZAP Surgical Systems, Inc.			
9:00		8:30~9:00 Special Lecture 2 Moderator: Ryo Nishikawa Lecturer: Hidefumi Aoyama Sponsor: Varian Medical Systems K.K.			
	Moderator: Susan Chang	9:00~9:15 Session 1 [Radiation Oncology]			
		9:15~9:45 Session 2 [Neuroimaging 1] Moderator: Manabu Kinoshita Sponsor: Nihon Medi-Physics Co., Ltd.			
10:00		9:45~10:13 Session 3 [Neuroimaging 2] Moderator: Manabu Kinoshita			
		10:13~10:23 Coffee break			
		10:23~11:25 Session 4 [Molecular Classification] Moderators: Guido Reifenberger Paul Northcott Pieter Wesseling			
11:00		11:25~11:55 Session 5 [Glioma heterogeneity/microenvironment] Moderator: Jason Huse Sponsor: Chimerix, Inc.		Exhibition	
		12:05~13:04 Luncheon Seminar 1 [Genomic Medicine] Moderator: Koichi Ichimura Sponsor: KONICA MINOLTA REALM, INC.			
13:00	Registration				
		13:09~14:36 Session 6 [Genetics/Precision Medicine] Moderators: David Ashley Simon Gregory Pim French			
		14:36~15:02 Session 7 [Viral therapy / Immunotherapy 1] Moderator: Tomoki Todo			
		15:02~15:41 Session 8 [Neurosurgery] Moderator: Yukihiko Sonoda Sponsor: S&Brain Corporation			
16:00			15:41~15:51 Coffee break		
			15:51~16:06 QIAGEN Presentation		
			16:06~16:49 Young Investigator's Session Moderator: Koichi Ichimura Sponsor: QIAGEN K.K.		
17:00					
18:00	18:00~20:00 Welcome Reception				
		18:30~20:30 Conference Dinner			
19:00					
20:00					

Day 3 (June 24)			Day 4 (June 25)		
Session Room 1 (Windsor Hall A-C)		Exhibition/Registration (Lobby)	Session Room 1 (Windsor Hall A-C)		Exhibition/Registration (Lobby)
8:00	8:00~9:00 Session 9 [Adult Glioma] Moderators: Michael Weller, Patrick Wen Sponsor: Ohara Pharmaceutical Co., Ltd.	Exhibition	8:00~9:05 Session 12 [Molecular biology] Moderators: Daisuke Kawauchi Russel Pieper	Exhibition	Registration
9:00	9:00~9:30 Special Lecture 3 Moderator: Yoshiki Arakawa Sponsor: NIHON SERVIER CO., LTD.		9:05~10:11 Session 13 [Pediatric Neuro-Oncology] Moderators: Annie Huang Chris Jones		
	9:30~9:40 Coffee break		10:11~10:21 Coffee break		
10:00	9:40~11:10 Session 10 [Epigenetics and Metabolism] Moderators: Sabine Mueller Suzanne Baker Hirokazu Takami Sponsor: Chimerix, Inc.		10:21~11:21 Session 14 [Preclinical Experimental Therapeutics/Tumor Models] Moderators: Daniel Cahill, Erik Sulman		
11:00	11:10~11:25 Special Lecture 4 Moderator: Yoshitaka Narita Sponsor: ONO PHARMACEUTICAL Co., Ltd.		11:21~11:46 Session 15 [Viral therapy 2] Moderator: Kazuhiko Kurozumi		
	11:25~11:45 Session 11 [PCNSL] Moderator: Yoshitaka Narita		11:56~12:57 Luncheon Seminar 3 [Pediatric Neuro-Oncology] Moderators: Cassie Kline, James Rutka Sponsor: Gold Ribbon Network Foundation / Aflac Life Insurance Japan Ltd.		
12:00	11:55~12:55 Luncheon Seminar 2 [Adult Glioma] Moderator: Motoo Nagane Sponsor: Novocure K.K.		13:02~13:41 Session 16 [Immunotherapy 2] Moderator: Duane Mitchell Sponsor: NIHON SERVIER CO., LTD.		
13:00			13:41~14:06 Session 17 [Drug delivery/Other therapy] Moderator: Rintaro Hashizume		
14:00			14:06~14:36 Session 18 [Epidemiology/Neuroscience] Moderator: Stephen Sands		
			14:36~14:42 Closing remarks		
15:00					
16:00					
17:00					
18:00					
19:00					
20:00					

Program

PROGRAM

Monday, June 23

<Session Room 1>

7:45~7:55 **Opening remarks**

Koichi Ichimura (Japan)

7:55~8:00 **Housekeeping announcement**

Hirokazu Takami (Japan)

8:00~8:30 **Special Lecture 1 ZAP-X** (Sponsor: ZAP Surgical Systems, Inc.)

Moderator: **Koichi Ichimura (Japan)**

SL1

Radiation for Glioblastoma: A Pending Revolution

John R. Adler (USA)

8:30~9:00 **Special Lecture 2 Radiation Oncology**

(Sponsor: Varian Medical Systems K.K.)

Moderator: **Ryo Nishikawa (Japan)**

SL2

Optimizing Radiation Strategies for Brain Metastases: Balancing Tumor Control and Neurocognitive Preservation

Hidefumi Aoyama (Japan)

9:00~9:15 **Session 1 Radiation Oncology**

Moderator: **Susan Chang (USA)**

O-001

COGNITIVE DECLINE CAUSED BY CRANIAL RADIATION AND THERAPY FOR SYNAPTIC MODULATION

Shogo Ishiuchi (Japan)

O-002

ACCELERATOR-BASED BORON NEUTRON CAPTURE THERAPY, A RANDOMIZED CONTROLLED TRIAL FOR REFRACTORY RECURRENT HIGH-GRADE MENINGIOMAS

Shin-Ichi Miyatake (Japan)

O-003

MR-LINAC ON-LINE WEEKLY ADAPTIVE RADIOTHERAPY (RT) FOR NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM THE UNITED SINGLE ARM PHASE II TRIAL

James R. Perry (Canada)

9:15~9:45 **Session 2 Neuroimaging 1** (Sponsor: Nihon Medi-Physics Co., Ltd.)

Moderator: **Manabu Kinoshita (Japan)**

O-004

QUANTIFICATION OF VASCULAR AND CELLULAR ARCHITECTURE, OXYGEN METABOLISM, AND FUNCTIONAL CONNECTIVITY IN GLIOMAS USING DYNAMIC SAGE-EPI

Benjamin M. Ellingson (USA)

O-005

A generative AI for methadone PET image generation from MRI

Manabu Kinoshita (Japan)

9:45~10:13 **Session 3 Neuroimaging 2**

Moderator: Manabu Kinoshita (Japan)

O-006 CLINICAL TRANSLATION OF HYPERPOLARIZED CARBON-13 METABOLIC IMAGING IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Susan Chang (USA)

O-007 CHARACTERIZATION OF RECURRENT TUMOR AND TREATMENT RELATED EFFECT USING 18F-FLUOROETHYTYROSINE IN GLIOMAS: RESULTS FROM A PROSPECTIVE PHASE 2 TRIAL (UC-GLIOFET)

Javier E. Villanueva-Meyer (USA)

O-008 Prognostic impact of radiological patterns and systemic therapy on leptomeningeal metastases

Hideyuki Arita (Japan)

O-009 IMPROVING RADIATION TARGET VOLUME DEFINITION FOR GLIOBLASTOMA USING AI-DRIVEN PREDICTIONS OF TUMOR RECURRENCE FROM ADVANCED MRI

Janine M. Lupo (USA)

O-010 Clinical/imaging characteristics and treatment of recurrent germinoma

Fumiyuki Yamasaki (Japan)

10:13~10:23 *Coffee Break*

10:23~11:25 **Session 4 Molecular Classification**

Moderator: Guido Reifenberger (Germany)

Paul Northcott (USA)

Pieter Wesseling (Netherlands)

O-011 DISSECTING LONGITUDINAL TRAJECTORIES OF GLIOBLASTOMA ECOSYSTEMS BY SINGLE-CELL GENOMICS

Masashi Nomura (Japan)

O-012 Prediction of brain metastasis development with DNA methylation signatures

Gelareh Zadeh (Canada)

O-014 The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant

Emilie Le Rhun (Switzerland)

O-015 REFINING DIAGNOSTIC AND MOLECULAR UNDERSTANDING OF OLIGODENDROGLIOMAS

Giselle Y. Lopez (USA)

O-016 The tumor cell states and resistance to therapy of genetically predisposed and sporadic glioma

Antonio Iavarone (USA)

O-017 cIMPACT-NOW: ABOUT UPDATES AND BALANCING ACTS

Pieter Wesseling (Netherlands)

O-018 PROTEOMIC LANDSCAPE OF HUMAN BRAIN TUMORS

Andreas von Deimling (Germany)

O-019 ASTROBLASTOMA COMPRISES THREE MOLECULARLY AND CLINICALLY DISTINCT SUBTYPES CHARACTERIZED BY DIFFERENT FUSION GENES

Marcel Kool (Germany)

O-021 IMMUNOHISTOCHEMICAL EXPRESSION AND DIFFERENTIAL METHYLATION OF HOXB13 RELIABLY DISTINGUISHES MYXOPAPILLARY EPENDYMOMA FROM SPINAL EPENDYMOMA

Guido Reifenberger (Germany)

O-022 Phenotyping of lymphoid aggregations in brain tumors

Karl H. Plate (Germany)

11:25~11:55 **Session 5 Glioma heterogeneity/microenvironment**
(Sponsor: Chimerix, Inc.)

Moderator: Jason Huse (USA)

- O-023** Relearning glioma evolution and heterogeneity from a 3D whole tumor perspective
Joseph Costello (USA)
- O-024** Unveiling the Origins of Glioblastoma: Linking Developmental Programs to Suppression of the Innate Immune Response
David M. Ashley (USA)
- O-025** The epigenetic evolution of IDH-mutant oligodendrogliomas highlights modes of tumour progression and allows for molecular based grading
Pim French (Netherlands)
- O-026** Protein-based classification reveals an immune-hot subtype in IDH mutant astrocytoma with worse prognosis
Jiguang Wang (Hong Kong)
- O-027** GENOMIC HETEROGENEITY DRIVES DISTINCT INFILTRATION PATTERNS IN GLIOBLASTOMA
Bjarne Winther Kristensen (Denmark)

12:05~13:04 **Luncheon Seminar 1 Genomic Medicine**
(Sponsor: KONICA MINOLTA REALM, INC.)

Moderator: Koichi Ichimura (Japan)

- LS1-1** Molecular Targeted Therapies and Comprehensive Genomic Profiling for Brain Tumors in Japan: Current Status and Challenges
Shota Tanaka (Japan)
- LS1-2** LANDSCAPE OF NATIONWIDE COMPREHENSIVE GENOMIC PROFILING TESTING OF 974 ADULT CENTRAL NERVOUS SYSTEM TUMORS IN JAPAN
Masamichi Takahashi (Japan)
- LS1-3** MULTI-OMICS ANALYSIS REVEALS THE HOMOGENEITY AND MOLECULARLY NON-AGGRESSIVE CHARACTERISTICS OF CENTRAL NEUROCYTOMA
Hiromichi Suzuki (Japan)
- LS1-4** A Multi-Center Retrospective Study on Lower Grade Gliomas in Japan
Yoshiki Arakawa (Japan)
- LS1-5** Announcing the Asian Oceanian Society of Neuropathology guidelines for Adapting Diagnostic Approaches for Practical Taxonomy in Resource-Restrained Regions (AOSNP-ADAPTR)
Takashi Komori (Japan)
- LS1-6** Mutation Analysis of Brain Tumors from FFPE Material Using a Bench-Top Long-Read Sequencer
Kaishi Satomi (Japan)

13:09~14:36 **Session 6 Genetics/Precision Medicine**

Moderator: David Ashley (USA)
Simon Gregory (USA)
Pim French (Netherlands)

- O-028** DEVELOPMENT OF A NOVEL TERT PROMOTER MUTATION TARGET THERAPY BY CRISPR LIBRARY SCREENING USING IPSC-DERIVED GLIOBLASTOMA MODEL
Shunichiro Miki (Japan)
- O-029** UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA.
Timothy Cloughesy (USA)

- O-030 The origins of brain tumors: Insights into glioblastoma, IDH-mutant glioma, and meningioma
Seok-Gu Kang (Korea)
- O-031 The origins and dynamics of cell-free DNA in cerebrospinal fluid from patients with embryonal tumours
Sebastian M. Waszak (Switzerland)
- O-032 IDENTIFICATION OF RECURRENT GENETIC ALTERATIONS IN PINEOBLASTOMA SUBTYPES
Torsten Pietsch (Germany)
- O-033 LONGITUDINAL CHARACTERIZATION OF EXTRACHROMOSOMAL DNA AMPLIFICATIONS IN ADULT GLIOMA COHORT
Hoon Kim (Korea)
- O-035 CHARACTERIZING THE IMMUNE-MICROENVIRONMENT OF BREAST AND LUNG CANCER BRAIN METASTASES REVEALS PROGNOSTICALLY RELEVANT IMMUNE LANDSCAPES
Christel Claudia Herold-Mende (Germany)
- O-036 Determinants of Tumor-Infiltrating Lymphocyte (TIL) Expansion in High-Grade Gliomas through Multimodal Profiling
Mustafa Khasraw (USA)
- O-037 VARIATION AMONG INTACT TISSUE SAMPLES REVEALS THE CORE TRANSCRIPTIONAL FEATURES OF CELL TYPES AND STATES IN ADULT MALIGNANT GLIOMAS
Michael C. Oldham (USA)
- O-038 PHASE 0/1 TRIAL OF BDTX-1535 FOR RECURRENT WHO GRADE 3-4 GLIOMAS WITH EGFR ALTERATIONS
Yoshie Umemura (USA)
- O-039 Clinical Characteristics of Optic Pathway Hypothalamic Low-grade Gliomas harboring FGFR1 mutation
Shigeru Yamaguchi (Japan)
- O-040 Molecular Insights, Personalized Medicine: Transforming Patient Care through Precision Biology
Simon G. Gregory (USA)
- O-041 DNA hypomethylator phenotype reprograms oncogenic neuron-glioma network in glioblastoma
Kenta Masui (Japan)
- O-042 Tumor-immune evolution at recurrence
Joanna J. Phillips (USA)
- O-043 A randomized, placebo-controlled phase III trial of an autologous formalin-fixed tumor vaccine (Cellm-001) for newly diagnosed glioblastoma
Yoshihiro Muragaki (Japan)

14:36~15:02 **Session 7 Viral therapy 1 / Immunotherapy 1**

Moderator: Tomoki Todo (Japan)

- O-123 PHASE I TRIAL OF MESENCHYMAL STEM CELLS CARRYING DELTA-24-RGD GIVEN INTRAARTERALLY IN RECURRENT GLIOMA: INITIAL REPORT
Frederick F. Lang (USA)
- O-124 Non-lytic replicating viral delivery of an IL-15 superagonist enhances antitumor immunity and extends survival in glioblastoma
Manish K. Agbi (USA)
- O-130 NEOADJUVANT ANTI-PD1 TREATMENT IN RECURRING RESECTABLE GLIOBLASTOMA: IMMUNE RESPONSE AND MOLECULAR INSIGHTS
Manfred Westphal (Germany)

15:02~15:41 **Session 8 Neurosurgery** (Sponsor: S&Brain Corporation)

Moderator: Yukihiro Sonoda (Japan)

-
- O-044 Visual Foundation Model for Fast, Label-free Detection of Diffuse Glioma Infiltration During Surgery
Mitchel S. Berger (USA)
- O-045 The importance of fluorescence-guided resection and the histological growth pattern in brain metastases
Nils Ole Schmidt (Germany)
- O-046 Introduction of a novel prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: a report by the RANO resect group
Philipp Karschnia (Germany)
- O-047 Survival outcome and prognostic factors in patients with insular gliomas undergoing intraoperative awake brain mapping
Kazuya Motomura (Japan)
- O-048 AI-ASSISTED VIRTUAL REALITY SURGICAL REHEARSAL IN GLIOMA SURGERY
Tae Hoon Roh (Korea)
- O-049 A phase III randomized trial of gross total resection versus possible resection of FLAIR hyperintensity lesion on MR image for newly diagnosed supratentorial glioblastoma
Yukihiro Sonoda (Japan)
- O-050 Transsylvian Approach for Radical Resection of Insular Gliomas: Emphasizing The Importance of The Transsylvian Approach for Elderly Patients with Zone II Insular Gliomas
Toshihiro Kumabe (Japan)

<Session Room 2>

15:51~16:49 **Young Investigator's Session** (Sponsor: QIAGEN K.K.)

Moderator: Koichi Ichimura (Japan)

-
- QIAGEN Presentation
- O-051 BRD4::LEUTX fusion exerts its oncogenic properties via a novel transcriptomic machinery
Arata Tomiyama (Japan)
- O-052 LONG-TERM TREATMENT WITH THE MUTANT IDH INHIBITOR DS-1001B INHIBITS THE GROWTH OF IDH1 MUTANT GLIOMAS AND INDUCES EPIGENETIC MODIFICATIONS IN VITRO AND IN VIVO
Kenji Fujimoto (Japan)
- O-053 Translating basic research on immunotherapy for glioblastoma into an investigator-initiated clinical trial
Yoshihiro Otani (Japan)
- O-054 Unraveling the Origin of Butterfly Glioblastoma: Does It Solely Arise from the Cerebral Hemispheres?
Ichiyo Shibahara (Japan)
- O-055 IDENTIFICATION OF GENETIC ALTERATIONS AND POTENTIAL THERAPEUTIC TARGETS IN HIGH-GRADE MENINGIOMAS USING CANCER GENE PANEL TESTING
Shigeo Ohba (Japan)
- O-056 Imaging Features and Progression Pattern of Diffuse Hemispheric Gliomas, H3 G34-mutant
Fumiharu Ohka (Japan)
- O-057 GAS6-Mediated Proliferation Advantage under Starvation in RNF213-Deficient Medulloblastoma Contrasts with Growth Defects in Standard Condition
Yohei Mineharu (Japan)

Tuesday, June 24

<Session Room 1>

8:00~9:00 **Session 9 Adult Glioma** (Sponsor: Ohara Pharmaceutical Co., Ltd.)

Moderator: Michael Weller (USA)
Patrick Wen (USA)

O-058 Updated results of Phase 3 STELLAR study showing eflornithine improves overall survival (OS) and progression free survival (PFS) in patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma
Howard Colman (USA)

O-059 A UNIFIED PHARMACODYNAMIC AND PHARMACOKINETIC ANALYSIS OF PARP-MEDIATED RADIOSENSITIZATION IN PATIENTS WITH GLIOBLASTOMA
Nader Sanai (USA)

O-060 PRELIMINARY RESULTS OF A PHASE 1 STUDY OF AUTOLOGOUS ANTI-EGFRVIII SYNNOTCH RECEPTOR INDUCED ANTI-EPHA2/IL-13R α 2 CAR (E-SYNC) T CELLS IN ADULT PARTICIPANTS WITH EGFRVIII+ GLIOBLASTOMA
Jennifer L. Clarke (USA)

O-061 PRIOR VORASIDENIB THERAPY ENHANCES SALVAGE CHEMORADIATION EFFICACY IN A GENETIC MOUSE MODEL OF IDH INHIBITOR RESPONSIVE GLIOMA
Samuel K. McBrayer (USA)

O-062 GENETIC LANDSCAPE IN IDH MUTANT LOWER GRADE GLIOMAS STRATIFIED BY AGE
Katherine B. Peters (USA)

O-063 Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase 2/3 Bayesian Randomized Platform Trial
Patrick Wen (USA)

O-064 A PROSPECTIVE, RANDOMIZED, SINGLE-CENTER TRIAL OF TTF TOGETHER WITH RADIATION THERAPY AND TEMOZOLOMIDE, COMPARED TO TEMOZOLOMIDE AND RADIATION THERAPY, CONTINUED BY TEMOZOLOMIDE AND TTF IN PATIENTS WITH NEWLY DIAGNOSED GBM
Rachel Grossman (Israel)

O-065 EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
John de Groot (USA)

O-066 Cellular plasticity leading to treatment resistance in gliomas
Chul-Kee Park (Korea)

O-067 ACCOUNTING FOR HETEROGENEITY IN GLIOBLASTOMA DRUG SCREENING MODELS
Sarah Best (Australia)

O-068 The tumoral molecular landscape of long-term survivors with glioblastoma, isocitrate dehydrogenase wildtype glioblastoma: lessons from ETERNITY (EORTC 1419)
Michael Weller (Switzerland)

9:00~9:30 **Special Lecture 3 Immunotherapy**
(Sponsor: NIHON SERVIER CO., LTD. MEDICAL & PATIENT AFFAIRS)

Moderator: Yoshiki Arakawa (Japan)

SL3 Immuno-genomic analysis elucidates immunosuppressive mechanisms in the tumor microenvironment
Hiro Yoshi Nishikawa (Japan)

9:30~9:40 **Coffee Break**

9:40~11:10 **Session 10 Epigenetics and Metabolism** (Sponsor: Chimerix, Inc.)

Moderator: Sabine Mueller (USA)
Suzanne Baker (USA)
Hirokazu Takami (Japan)

-
- O-069** EPIGENETIC AND TRANSCRIPTIONAL DEPENDENCIES IN HISTONE MUTANT GLIOMA
Suzanne J. Baker (USA)
- O-070** Perioperative clinical trial reveals decreased synaptic signaling and altered metabolism as consequences of mutant IDH inhibition
James Richard Whittle (Australia)
- O-071** CLINICAL AND MOLECULAR CHARACTERISTICS OF DIFFUSE NON-MIDLINE GLIOMAS WITH H3F3A GENE MUTATION IN THE KANSAI MOLECULAR DIAGNOSIS NETWORK FOR CNS TUMORS (KANSAI NETWORK): MULTICENTER RETROSPECTIVE COHORT STUDY
Yonehiro Kanemura (Japan)
- O-072** LACTYLATION FUELS NUCLEOTIDE BIOSYNTHESIS AND FACILITATES DEUTERIUM METABOLIC IMAGING OF TUMOR PROLIFERATION IN H3K27M-MUTANT GLIOMAS
Pavithra Viswanath (USA)
- O-073** SPATIAL MULTI-MODAL OMICS PROFILING OF THE INFILTRATIVE EDGE IN IDH-MUTATED GLIOMA
Saskia Freytag (Australia)
- O-074** TARGETING EPIGENETIC DRIVERS OF GBM USING AN MRNA-BASED EPIGENOME MEMORY EDITOR
John Liu (USA)
- O-075** Methylation based subclassification of glioblastoma. its clinical utility and biomarker discovery
Franz Lennard Ricklefs (Germany)
- O-076** GENOME-WIDE CHROMATIN DYSFUNCTION ENGAGES LINEAGE-DEFINING CORE REGULATORY CIRCUITS TO DISRUPT DIFFERENTIATION IN ATRX-DEFICIENT GLIOMA
Jason T. Huse (USA)
- O-077** The genomic landscape of primary mismatch repair deficient glioma provide insights on tumorigenesis and immunotherapy
Uri Tabori (Canada)
- O-078** EPIGENETIC DEPENDENCE IN PEDIATRIC GLIOMA: INSIGHT INTO DNA DAMAGE REPAIR AND TRANSCRIPTION ELONGATION
Rintaro Hashizume (Japan)
- O-079** Targeting Energy Metabolism in Malignant Gliomas and Tumor Microenvironment by NAMPT Inhibition
Vinay K. Puduvalli (USA)
- O-080** Multi-dimensional tumor cell plasticity promotes glioblastoma heterogeneity and therapeutic resistance
Jeremy N. Rich (USA)
- O-081** METABOLIC ADAPTATIONS OF GLIOBLASTOMA DURING TUMOR RELAPSE
Thomas Daubon (France)
- O-082** AP-1 ACTIVATION MEDIATES T CELL DYSFUNCTION IN GLIOBLASTOMA
Malte Mohme (Germany)
- O-083** Clinical effect of ketogenic diet combined with standard therapy including bevacizumab for malignant glioma
Takashi Sasayama (Japan)

11:10~11:25 **Special Lecture 4 PCNSL** (Sponsor: ONO PHARMACEUTICAL Co., Ltd.)

Moderator: Yoshitaka Narita (Japan)

SL4 A SECOND GENERATION BRUTON'S TYROSINE KINASE (BTK) INHIBITOR TIRABRUTINIB IN THE TREATMENT OF PRIMARY CNS LYMPHOMA
Motoo Nagane (Japan)

11:25~11:45 **Session 11 PCNSL**

Moderator: Yoshitaka Narita (Japan)

O-084 TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 PROSPECT STUDY
Tracy Batchelor (USA)

O-085 R-MPV followed by maintenance MPV for newly diagnosed primary CNS lymphoma in elderly patients
Kazuhiko Mishima (Japan)

O-086 Novel patient-derived xenograft models from Central Nervous Lymphoma patients for translational research
Kensuke Tateishi (Japan)

11:55~12:55 **Luncheon Seminar 2 Adult Glioma** (Sponsor: Novocure K.K.)

Moderator: Motoo Nagane (Japan)

LS2-1 Phase I/II Study of Maintenance Therapy with Metformin and Temozolomide targeting Cancer Stem Cells for Newly Diagnosed Glioblastoma
Yoshitaka Narita (Japan)

LS2-2 Cerebral blood flow and histological analysis for the accurate differentiation of infiltrating tumor and vasogenic edema in glioblastoma
Yoshiko Okita (Japan)

LS2-3 DYNAMIC CHANGES IN DNA HYDROXYMETHYLATION DURING MALIGNANT PROGRESSION OF IDH-MUTANT GLIOMAS
Akitake Mukasa (Japan)

LS2-4 D-ASPARAGINE AS A URINE BIOMARKER FOR GLIOBLASTOMA
Mitsutoshi Nakada (Japan)

LS2-5 Glutaminolysis is Associated with Mitochondrial Pathway Activation and Can Be Therapeutically Targeted in Glioblastoma
Koji Yoshimoto (Japan)

LS2-6 Utility of Rapid Molecular Diagnosis in Glioma Surgery
Ryuta Saito (Japan)

Wednesday, June 25

8:00~9:05 **Session 12 Molecular biology**

Moderator: Daisuke Kawauchi (Japan)
Russel Pieper (USA)

- O-087** Transcription Factor Mediated Rescue of Glioblastoma Differentiation Failure
Peter Dirks (Canada)
- O-088** TUMOR-WIDE RNA SPLICING ABERRATIONS GENERATE ACTIONABLE PUBLIC NEOANTIGENS
Hideho Okada (USA)
- O-089** THE EVOLUTION OF THE TUMOR AND IMMUNE SYSTEM AFTER CAR T CELL THERAPY IN RECURRENT GBM
Dana Silverbush (USA)
- O-090** AUTOPHAGY MODULATES GLIOBLASTOMA CELL SENSITIVITY TO SELINEXOR-MEDIATED XPO1 INHIBITION
Russell O. Pieper (USA)
- O-091** TESTOSTERONE FUNCTIONS AS A TUMOR SUPPRESSOR IN THE BRAIN VIA ABERRANT ACTIVATION OF THE HPA AXIS, DRIVING IMMUNE SUPPRESSION
Justin D. Lathia (USA)
- O-092** REPROGRAMMING OF MYELOPOIESIS IN MUTANT IDH 1 GLIOMAS ENHANCES THE RESPONSE TO IMMUNE MEDIATED THERAPIES
Maria G. Castro (USA)
- O-094** METRNL Cytokine Drives Immune Cell Exhaustion in Tumor Infiltrating Lymphocytes by Inducing Bioenergetic Dysregulation
Michael Lim (USA)
- O-119** Bcl-xL inhibition targets senescent glioblastoma cells post temozolomide treatment to induce apoptosis
Fumi Higuchi (Japan)
- O-095** IMMUNE DEPENDENCY OF ANTI-VEGF TREATMENT EFFICACY AGAINST GLIOMA
Katrin Lamszus (Germany)
- O-096** A FULLY DIFFERENTIATED RAT BRAIN ORGANOID MODEL FOR EXPLORING GLIOBLASTOMA INVASION DYNAMICS AND THERAPY
Rolf Bjerkvig (Norway)
- O-097** Exploring Fibronectin Subtypes for Prognosis Prediction and Therapeutic Targeting in Malignant Glioma
Kyuha Chong (Korea)

9:05~10:11 **Session 13 Pediatric Neuro-Oncology**

Moderator: Annie Huang (Canada)
Chris Jones (UK)

- O-098** Molecular Mechanisms and Developmental Pathways of Central Nervous System Germ Cell Tumors Elucidated through Whole Genome Analysis
Hirokazu Takami (Japan)
- O-099** A whole genome Nanopore sequencing analysis suggested distinct mechanisms of development in central nervous system germ cell tumors
Koichi Ichimura (Japan)
- O-100** Initiation and birth dating of medulloblastoma
Stefan M. Pfister (Germany)

- O-101** Deciphering the Epigenomic Landscape of SHH-Medulloblastoma: Regulatory Mechanisms and Therapeutic Insights
Daisuke Kawauchi (Japan)
- O-102** EPIGENETIC UPREGULATION OF SCHLAFEN11 RENDERS WNT- AND SHH- ACTIVATED MEDULLOBLASTOMAS SENSITIVE TO CISPLATIN
Manabu Natsumeda (Japan)
- O-103** Blockade of insulin signaling cooperates with PI3K inhibitors to suppress MYCN pediatric high-grade glioma growth
Sameer Agnihotri (Canada)
- O-104** GENETIC ANCESTRY SUPERPOPULATIONS REVEAL DIFFERENT PREVALENCE, OUTCOMES, AND TREATMENT ACROSS PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS FROM PBTA AND PNOC
Cassie Kline (USA)
- O-105** PHOSPHOTYROSINE INTERACTION DOMAIN-CONTAINING 1 (PID1), A GROWTH INHIBITOR IN GLIOMAS AND MEDULLOBLASTOMAS, IS A NOVEL MEDIATOR IN THE HIPPO SIGNALING PATHWAY
Anat Erdreich-Epstein (USA)
- O-106** HEAD START 4 SONIC HEDGEHOG (SHH) MEDULLOBLASTOMA: 2 YEAR FOLLOW-UP
Stephen A. Sands (USA)
- O-107** ASTROBLASTOMAS WITH BEND2 FUSION SHOWING EXTENSIVE CARCINOMA-LIKE EPITHELIAL DIFFERENTIATION MIMICKING METASTATIC ADENOCARCINOMA
Sumihito Nobusawa (Japan)
- O-108** Clinical and molecular characterization of infantile central nervous system germ cell tumors
Kohei Fukuoka (Japan)
- O-109** Single center analysis of a phase II trial of dabrafenib plus trametinib in BRAF V600 mutant pediatric low grade glioma and relapsed/refractory BRAF V600 mutant pediatric high grade glioma
Keita Terashima (Japan)

10:11~10:21 *Coffee Break*

10:21~11:21 **Session 14 Preclinical Experimental Therapeutics/Tumor Models**

Moderator: Daniel Cahill (USA)
Erik Sulman (USA)

- O-110** RAS(ON) MULTI-SELECTIVE TRI-COMPLEX INHIBITOR SHOWS SINGLE AGENT ACTIVITY AND COOPERATE WITH INHIBITORS OF EIF4A IN PRECLINICAL MODELS OF GLIOBLASTOMA
William A. Weiss (USA)
- O-111** A novel, pooled, high-throughput screening of a CNS penetrant compound library identifies potential biomarker-driven therapeutics for glioblastoma
Erik Sulman (USA)
- O-112** TARGETING AXONAL GUIDANCE DEPENDENCIES IN GLIOBLASTOMA WITH ROBO1 CAR T CELLS
Sheila Kumari Singh (Canada)
- O-113** PRECLINICAL STUDIES OF MICROBUBBLE MEDIATED NON-THERMAL FOCUSED ULTRASOUND FOR INTRACRANIAL TUMOR ABLATION
Randy Jensen (USA)
- O-114** Integrative multiomics combined with functional pharmacological profiling in patient-derived preclinical models for the identification of personalized therapeutic vulnerabilities of high-grade gliomas
Anna Golebiewska (Luxenburg)

- O-115** Designer integrin signaling blocking peptides that reprogram the immunosuppressive tumor microenvironment and vasculature improve anti-PD-1 immunotherapy in brain tumors
Bozena Kaminska (Poland)
- O-116** COLLAGEN RECEPTOR LAIR-1 MODULATES FIBROSIS, IMMUNE INFILTRATION, AND THERAPEUTIC RESPONSES IN EXPERIMENTAL MODELS OF GLIOMA
Pedro Lowenstein (USA)
- O-117** RATIONAL DESIGN OF CELLULAR THERAPIES TO OVERCOME TUMOR HETEROGENEITY AND IMMUNOSUPPRESSION IN GLIOBLASTOMA
Anoop P. Patel (USA)
- O-118** INHIBITION OF MIR-146A DECREASES PROGRESSION OF MELANOMA BRAIN METASTASIS
Frits Thorsen (Norway)
- O-120** ADC drug discovery based on the unmet medical needs
Do-Hyun Nam (Korea)
- O-121** Replication stress checkpoints in IDH mutant glioma can be selectively targeted in combination with radiation therapy
Daniel P. Cahill (USA)
- O-122** Unraveling Immune Evasion Mechanisms and Pioneering Immune Revitalization Strategies in Malignant Brain Tumors
Ying Mao (China)

11:21~11:46 **Session 15 Viral therapy 2**

Moderator: Kazuhiko Kurozumi (Japan)

- O-125** Development of a novel oncolytic herpes virus with reduced tumor swelling for malignant glioma
Tomoki Todo (Japan)
- O-126** Immunovirotherapy for Recurrent Glioblastoma using Measles Virus Strains Expressing the Toll-like receptor 2 (TLR2) agonist Neutrophil Activating Protein (NAP)
Evanthia Galanis (USA)
- O-127** EXPAND AND PULL: A NEW WAY TO BOOST THE ANTI-TUMOR RESPONSE IN GBM
Milan G. Chheda (USA)
- O-128** Suicide Gene Therapy for Brain Tumors Using SHED Expressing HSV-TK
Kazuhiko Kurozumi (Japan)
- O-129** IDH STATUS DICTATES OHSV MEDIATED METABOLIC REPROGRAMMING AFFECTING ANTI-TUMOR IMMUNITY
Balveen Kaur (USA)

11:56~12:57 **Luncheon Seminar 3 Pediatric Neuro-Oncology**
(Sponsor: Gold Ribbon Network Foundation / Aflac Life Insurance Japan Ltd.)

Moderator: Cassie Kline (USA)
James Rutka (Canada)

- LS3-1** ROBUST DETECTION, CLASSIFICATION, AND MONITORING OF PEDIATRIC BRAIN TUMORS FROM CELL-FREE DNA METHYLOMES
Paul A. Northcott (USA)
- LS3-2** ZSCAN4 mediates telomere repair in group 3 medulloblastomas and is targetable for therapeutic benefit
Aaron Diaz (USA)
- LS3-3** Generation of improved, clinically-relevant models of atypical teratoid rhabdoid tumors
James Thomas Rutka (Canada)

- LS3-4** PNOC022 report: a combination therapy trial using an adaptive platform design for patients with diffuse midline glioma at initial diagnosis, post-radiation therapy, or progression
Sabine Mueller (USA)
- LS3-5** REGULATION OF GABAERGIC INTERNEURON CELL FATE IN EMBRYONIC FOREBRAIN AND TARGETING THE CELL OF ORIGIN OF DIFFUSE HEMISPHERIC GLIOMA
David D. Eisenstat (Australia)
- LS3-6** Unravelling selective, targetable dependencies in ACVR1-mutant diffuse midline glioma
Chris Jones (UK)
- LS3-7** MicroRNA CAN PROMOTE SENESENCE IN PEDIATRIC LOW GRADE GLIOMA
Charles Eberhart (USA)
- LS3-8** PNOC008: A PILOT TRIAL TESTING THE CLINICAL BENEFIT OF USING MOLECULAR PROFILING TO DETERMINE AN INDIVIDUALIZED TREATMENT PLAN IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (EXCLUDING DIFFUSE INTRINSIC PONTINE GLIOMA): UNIVERSITY OF CALIFORNIA SAN FRANCISCO (USA)
Michael D. Prados (USA)
- LS3-9** C19MC LEVERAGES DNA DAMAGE REPAIR PATHWAYS TO DRIVE ETMR TUMORIGENESIS
Annie Huang (Canada)
- LS3-10** OUTCOMES BY CLINICAL AND MOLECULAR RISK-FACTORS, INCLUDING NEUROCOGNITIVE LATE-EFFECTS, FOR INFANTS AND YOUNG CHILDREN WITH NEWLY DIAGNOSED SHH MEDULLOBLASTOMA TREATED ON HEAD START 4 (HS4) CLINICAL TRIAL
Girish Dhall (USA)

13:02~13:41

Session 16 Immunotherapy 2

(Sponsor: NIHON SERVICER CO., LTD. MEDICAL & PATIENT AFFAIRS)

Moderator: Duane Mitchell (USA)

- O-131** DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES
Robert M. Prins (USA)
- O-133** RNA-BASED IMMUNOTHERAPIES TARGETING MALIGNANT BRAIN TUMORS
Duane A. Mitchell (USA)
- O-134** Preliminary results of a phase II study of stereotactic radiosurgery in conjunction with the PD-1 inhibitor Pembrolizumab for the treatment of recurrent high-grade meningioma
Nancy Ann Oberheim Bush (USA)
- O-135** INVESTIGATION OF THE COMBINATION OF D2C7-IT WITH AN FC-ENGINEERED ANTI-HUMAN CD40 MONOCLONAL ANTIBODY (2141-V11) WHEN ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGM)
Annick Desjardins (USA)
- O-136** IMMUNE PROFILING IN PERIPHERAL BLOOD PREDICTS TREATMENT RESPONSE AND SURVIVAL IN GLIOBLASTOMA PATIENTS RECEIVING PD-L1 IMMUNOTHERAPY
Annette Molinaro (USA)
- O-137** PHASE 1/2 TRIAL OF A WT1 PEPTIDE-DOSING EMULSION IN CHILDREN WITH RECURRENT/REFRACTORY DIFFUSE INTRINSIC PONTINE GLIOMA, GLIOBLASTOMA, OR ANAPLASTIC ASTROCYTOMA
Naoya Hashimoto (Japan)
- O-138** p53 and PIK3R2 immunostaining status as prognostic predictive factors of autologous tumor vaccine for initially diagnosed glioblastoma
Eiichi Ishikawa (Japan)

13:41~14:06 **Session 17 Drug delivery/Other therapy**

Moderator: Rintaro Hashizume (Japan)

O-139 ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER OPENING IN CONJUNCTION WITH CARBOPLATIN/NAB-PACLITAXEL CHEMOTHERAPY FOR PATIENTS WITH FIRST RECURRENCE GLIOBLASTOMA. INITIAL RESULTS OF A PHASE 2 STUDY.

Roger Stupp (USA)

O-140 TARGETING NON-APOPTOTIC CELL DEATH IN GLIOBLASTOMA

David Allan Nathanson (USA)

O-141 Clinical Benefits of Photodynamic Therapy Using Talaporfin Sodium in Patients with Isocitrate Dehydrogenase-Wild Type Diagnosed Glioblastoma: A Retrospective Study of 100 Cases

Kazuhiro Tanaka (Japan)

O-142 ULTRASOUND-BASED BLOOD-BRAIN BARRIER OPENING WITH IMPLANTABLE ULTRASOUND AND MICROBUBBLES: PHARMACOKINETIC AND IMMUNE-RELATED IMPLICATIONS OF HOMEOSTASIS DURING RAPID REPAIR OF CAPILLARIES IN THE HUMAN BRAIN

Adam M. Sonabend (USA)

O-143 CO-DELIVERY OF PANOBINOSTAT AND siSTAT3 USING ENGINEERED M1 MACROPHAGE EXOSOMES FOR GBM RECURRENCE THERAPY

Jian Wang (Norway)

14:06~14:36 **Session 18 Epidemiology/Neuroscience**

Moderator: Stephen Sands (USA)

O-144 Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters

Elizabeth Brooks Claus (USA)

O-149 THE GENOMIC LANDSCAPE OF FAMILIAL GLIOMA

Melissa Bondy (USA)

O-146 Inflammatory Microglia Orchestrate Tumor-Neural Synaptogenesis in CNS Tumors

Dieter Henrik Heiland (Germany)

O-147 Electrophysiological and spatial profiling of glioma-infiltrated cortex reveals layer-specific neuronal population remodeling


Shawn L. Hervey-Jumper (USA)

O-148 SPATIAL SYNAPTIC CONNECTIVITY UNDERLIES OLIGODENDROGLIOMA EVOLUTION AND RECURRENCE

David R. Raleigh (USA)

14:36~14:42 **Closing remarks and handover**

Conference Chair: Koichi Ichimura (Japan), Conference Chair for ICBTRT 2027: Pim French (Netherlands)



抗悪性腫瘍剤 / トロポミオシン受容体キナーゼ阻害剤

薬価基準収載

ヴァイトラックビ[®] カプセル 25mg 100mg
内用液 20mg/mL

VITRAKVI[®] capsules 25mg/100mg
oral solution 20mg/mL

劇薬, 処方箋医薬品^{注)}

ラロトレクチニブ硫酸塩カプセル / 内用液

注) 注意一医師等の処方箋により使用すること

効能又は効果、用法及び用量、警告・禁忌を含む注意事項等情報の詳細については最新の電子添文をご参照ください。

弊社製品情報サイト(<https://www.vitrakvi.jp>)をご参照ください



Bayer

製造販売元 [文献請求先及び問い合わせ先]

バイエル薬品株式会社

大阪市北区梅田2-4-9 〒530-0001

<https://pharma.bayer.jp>

[コンタクトセンター]

0120-106-398

<受付時間> 9:00~17:30(土日祝日・当社休日を除く)

Drug for photodynamic diagnosis
5-Aminolevulinic Acid Hydrochloride

Alabel[®] Oral 1.5g

Registered as

- **Gliolan** 30 mg/ml powder for oral solution
 - **Gleolan** for oral solution
- in EU, US and other countries.

注) 医薬品処方箋

薬価基準収載

アラベル[®]内用剤 1.5g

注) 注意-医師 等の処方箋により使用すること。

重大な副作用として、肝機能障害や低血圧がございます。

効能・効果、用法・用量、禁忌を含む使用上の注意等については電子化された添付文書をご参照ください。



For the ideal Blue light
Aladuck[®]405
A Light Assistance system

You are welcome to contact us here as well.
<https://www.sbipharma.co.jp/en/contact/>



2024年10月より製造販売承認を承継致しました。

資料
請求先

製 造
販売元

SBI Pharma

SBIファーマ株式会社
東京都港区六本木一丁目6番1号

2025年4月作成

10x GENOMICS

究極のシングルセル 空間生物学を体験 Xenium Analyzer

位置情報を保持したまま、シングルセルの解像度で
組織中の数百から数千のRNAをin situ解析

10x Genomics

www.10xgenomics.com/jp

お問い合わせ japanmarketing@10xgenomics.com

10x Genomics Japan
最新ニュースはこちら



alfresa

時代が求める新たな“Unmet Medical Needs”に挑戦します

医薬、診断薬、医療機器などを開発・製造・販売する医療メーカーとして、
「予防」「診断」「治療」の全プロセスで医療を総合的にバックアップし、
世界中の人々の健康に貢献していきます。

アルフレッサ ファーマ株式会社

〒540-8575 大阪市中央区石町二丁目2番9号 TEL.06-6941-0300(代) FAX.06-6947-1548
<http://www.alfresa-pharma.co.jp>

CRYOSEAL[®]
SYSTEM

自己血漿から生まれる、生体組織接着剤



自動調製

クリオシールシステムは、患者血漿から生体組織接着剤の成分であるクリオプレシピテート（以下、クリオ）およびトロンビン液を滅菌閉鎖回路内で自動的に調製します。



凍結保存可能

調製されたクリオとトロンビン液は、28日間、凍結保存が可能です。手術時に解凍し、混和することにより、生体組織接着剤としての機能を果たします。



リスク回避

特定生物由来製品の使用による「感染」のリスクを完全に否定することができない」おそれを回避することが可能です。

血液成分分離キット
クリオシールディスポーザブルキット
(承認番号 22300BZX00371000)

血漿処理ユニット CP-3

トロンビン用添加液

噴霧器スプレーチップ
ST-3噴霧器ドットチップ
DT-10

噴霧器

クリオシールディスポーザブルキットは、「血漿処理ユニット CP-3 (1個)」、「トロンビン用添加液 (1個)」、「噴霧器 (2個 (1袋))」から構成されます。

血液成分分離用装置
クリオシール CS-1
(承認番号 22300BZX00372000)クリオシールシステム
ホームページ

旭化成メディカル株式会社

〒100-0006 東京都千代田区有楽町1-1-2 日比谷三井タワー

TEL: 03-6699-3771 www.asahikasei-medical.co.jp

No.2022.10-F-0588A5E1C

Turning complex into clarity.

ZEISS KINEVO 900 S

デジタルと
ロボティックの進化で
高難度手術の効率を追求



Best Digital Visualization

進化した4K3Dで確かな視覚化



Cobotic Assistant

協働ロボティクスによる手術支援

NEW



Seeing beyond

zeiss.com/kinevo

販売名：手術用顕微鏡 KINEVO 900 S

製造販売届出番号：13B1X00119003710

カールツァイスメディテック株式会社

〒102-0083 東京都千代田区麹町二丁目10番9号

TEL: 0570-021311 FAX: 03-5214-1251

JP_30_030_02421



★効能・効果、用法・用量、禁忌を含む
使用上の注意等については
添付文書をご参照ください。

特定生物由来製品 処方箋医薬品[※]
血漿分画製剤（生理的組織接着剤）

薬価基準収載



ベリプラスト[®] P コンビセット 組織接着用
Beriplast[®] P Combi-Set Tissue adhesion

注）注意—医師等の処方箋により使用すること

資料請求先：

CSLベーリング株式会社

〒107-0061 東京都港区北青山一丁目2番3号

くすり相談窓口 TEL：0120-534-587

JPN-BRP-3088
2024年8月作成

CSL Behring



世界中の人々の
健康で豊かな生活に貢献する

イノベーションに情熱を。ひとに思いやりを。



Daiichi-Sankyo

第一三共株式会社

GUNZE

吸収性体内固定用ネジ・吸収性体内固定用プレート

NEOFIXR

GUNZE MEDICAL

グンゼメディカル株式会社

Made in Japan

本製品の詳しい情報は、弊社ウェブサイトをご覧ください

製造販売業者 **グンゼメディカル株式会社**

各種資料の請求・購入その他のお問い合わせは、
グンゼメディカル株式会社までご連絡ください。

TEL : 06-4796-3151 FAX : 06-4796-3150

NEOFIXR

<https://gunzemedical.co.jp/product/neofix-r>

ネオフィックス R
高度管理医療機器 医療機器承認番号 30500BZX00029000



文書管理 No. P000524-1

※画像はイメージです。

池田理化は「理化学総合商社」として

これからも、先端科学の研究を支え続けます



研究活動の最前線で
未来づくりをサポートします。

We support the creation of the future at the
forefront of research activities.



株式会社 池田理化

<https://www.ikedarika.co.jp/>

本 社 〒101-0044 東京都千代田区鍛冶町1-8-6 神田KSビル
TEL:03-5256-1811 FAX:03-5256-1818

支 店 札幌、仙台、つくば、宇都宮、埼玉、千葉、八王子、小金井
横浜、鶴見、平塚、藤沢、三島、藤枝、名古屋、大阪、岩国

オフィス・営業所 東富士、豊田、新山口、沖縄

メディカルをシステムで考える

進化し続ける医療の世界に最適なソリューションを提供します。



株式会社 イノメディックス <https://www.innomedics.co.jp>

〒113-0034 東京都文京区湯島二丁目16番11号 TEL.03-3814-3647(代表) FAX.03-3815-8507

【営業拠点】本郷、小石川、国立、埼玉、千葉、鴨川、柏、つくば、横浜、相模原 【物流拠点】商品C、東京TC、東京SPDC

CUSA® Clarity
Ultrasonic Tissue Ablation System

「破碎効率」「出力精度」「組織選択」
求められる3つの特性すべてをひとつに

36 kHz
Handpiece

23 kHz
Handpiece

Power
Precision
Preservation

All in One.

INTEGRA

製造販売元

Integra Japan 株式会社

〒107-0052 東京都港区赤坂1-7-1 赤坂榎坂ビル

TEL:03-6809-0235 FAX:03-6809-0236

販売名:超音波手術器 CUSA Clarity
承認番号:23000BZX00065000


©Integra Japan K.K. 2023 • 3535625-1 • TR



(研究用試薬)

ヒストラ 1p31/1q25 and 19q13/19p13 FISHプローブセット


ヒストラ1p31/1q25 FISHプローブ



1p31 loss (欠失)




1p 正常



1p 欠失

ヒストラ19q13/19p13 FISHプローブ



19q13 loss (欠失)

※より詳しい情報につきましては、お問い合わせください。

- 1p/19qの同時全欠失は神経膠腫（グリオーマ）の中の乏突起膠腫（oligodendroglioma）との関係が示唆されています。
- 1p31/1q25プローブと19q13/19p13プローブはFISH法により1p31領域と19q13領域の欠失を検出します。
- 1p31/1q25プローブは1p31領域をローダミン、1q25領域をfluoresceinで標識しています。19q13/19p13プローブは19q13領域をローダミン、19p13領域をfluoresceinで標識しています。
- プローブは2本セット（1p31/1q25プローブと19q13/19p13プローブ）で提供しています。（未変性プローブ溶液）



ヒストラHER2FISH補充用 前処理キット

ホルマリン固定パラフィン包埋切片の前処理には、ヒストラHER2FISH補充用前処理キットのご使用をお勧めいたします。

その他、各種FISHプローブも取り揃えております。

株式会社 常光 営業サービス部
〒213-8588 神奈川県川崎市高津区宇奈根 731-1
TEL 044-811-9211(代) FAX 044-811-9204



1p (1p31) / 19q (19q13)
FISH プローブ



CM1950



BOND RX



VT 1200 S

Leica
BIOSYSTEMS

ライカ マイクロシステムズ株式会社 ライカ バイオシステムズ事業本部

販売名 販売名 ライカ CM1950
医療機器製造販売届出番号 : 13B2X10268CM0003

- 東京本社 〒169-0075 東京都新宿区高田馬場 1-29-9
- 大阪支店 〒531-0072 大阪市北区豊崎5-4-9 商業第2ビル10F
- 名古屋支店 〒460-0008 名古屋市中区栄2-3-31 CK22キリン広小路ビル5F
- 福岡支店 〒812-0025 福岡市博多区店屋町8-30 博多フコク生命ビル12F

- Tel. 03-6758-5690 Fax.03-5155-4337
- Tel. 06-6374-9770 Fax.06-6374-9772
- Tel. 052-222-3939 Fax.052-222-3784
- Tel. 092-282-9771 Fax.092-282-9772



Medtronic

Engineering the extraordinary

1秒に2人

人々の生活を毎時間、毎日、
変え続けています

メドトロニックは、人生を
変えるようなテクノロジーで
70種類以上の健康課題に対する
治療法を提供してきました。

私たちの製品、サービス、
そしてソリューションによって、
年間7,600万人の患者さんが、
世界のどこかで意義のある
生活を取り戻しています。

詳しくはこちら

メドトロニック 検索

medtronic.co.jp



© 2023 Medtronic. Medtronic、メドトロニック、Medtronicロゴマーク及びEngineering the extraordinaryは、Medtronicの商標です。COMMS-2024-0006



MIZUHO

Medical Innovation

医療を支え、未来を創造する。

私たちミズホは、世界から寄せられるさまざまな
声を真摯に受け止め、グローバルな視点で新しい
価値の創造に挑みつづけ、人々の健やかな
未来のために一丸となって邁進してまいります。

ミズホ株式会社

MIZUHO Corporation

〒113-0033 東京都文京区本郷3-30-13 TEL 03-3815-3191 FAX 03-3815-3181 <http://www.mizuho.co.jp>



汎用電動式手術台
MOT-VS600Dj



脳動脈瘤手術用クリップ
杉田チタンクリップⅡ



Prostock-Studio © Getty Images - NOVEMBRE 2022 - 23/11/71A

**An independent group
committed to
therapeutic progress
to serve patient needs**

私たちは、
患者さまのニーズに応えるため
治療の向上に取り組んでいます。

SERVIER★
moved by you

日本セルヴィエ株式会社


<https://nihonservier.co.jp>



DESIGNS FOR VISION, Inc.

REVEAL™ FGS
Wearable Fluorescence Guided System

REVEAL FGS トライビーム



一般的な白色光1つと、波長の異なる青色光2つを有するライトです。

- 青色光の波長は405nm(蛍光ガイドの際の励起光)と450nm(蛍光ガイドの際の後方散乱光)の2種類。

製造販売元
OHWA 欧和通商株式会社

第1種医療機器製造販売業許可番号:13B1X00167

東京営業所 TEL:03(3813)8201 福岡営業所 TEL:092(526)3618
大阪営業所 TEL:06(6304)9305 札幌営業所 TEL:011(708)7725
<http://www.ohwa-tsusho.com>

販売名:REVEAL FGS トライビーム
一般的名称:額帯灯
届出番号:13B1X00167000331

AD25042502

ラボ空間の最適環境づくりを お手伝いします。

研究用試薬
臨床検査薬
O A 機器

研究用総合機器
臨床検査用機器
事務用機器

尾崎理化株式会社

本 社	〒252-0153	神奈川県相模原市緑区根小屋1888 電話 042(784)2525 FAX 042(784)2555 E-mail:honsha@ozakirika.co.jp URLhttp://www.ozakirika.co.jp/
横浜営業所	〒226-0028	横浜市緑区いぶき野31-10 電話 045(988)0531 FAX 045(988)0532 E-mail:yokohama@ozakirika.co.jp
多摩営業所	〒192-0907	東京都八王子市長沼町200-6 電話 042(637)2200 FAX 042(632)7212 E-mail:tama@ozakirika.co.jp
川崎営業所	〒210-0852	神奈川県川崎市川崎区鋼管通1-3-3 電話 044(329)1414 FAX 044(329)1755 E-mail:kawasaki@ozakirika.co.jp



人類の歴史にはさまざまな挑戦者がいた。
どんなに失敗しても、彼らの熱意や想いが
何度も立ち上がらせ、その結果、常識を
打ち破り新しい世界を見せてくれた。
医薬はどうだ。
世界一高い山に登り、宇宙や深海を探索
できる時代に、私たちの体の中には未解決
の課題が山積している。
私たちにはやるべきことがある。
助けなければならない人がいる。
だから、挑む。住友ファーマ



Sumitomo Pharma
Innovation today, healthier tomorrows



Stereo-seq

STOmics | MGI

サブセルレベルの空間解析!

全発現遺伝子を対象
ナノスケールの解像度
多様な生物種に対応
広い視野での観察可
FFPE と 新鮮凍結組織対応



Chen, A., Sun, Y., Lei, Y., Liu, Z., Xu, X., Li, C., et al. (2023).
Single-cell spatial transcriptome reveals cell-type organization in the macaque cortex. Cell, 186(17), 3726-3743.e24.



●総販売元
住商ファーマインターナショナル 株式会社
研究推進部 バイオサイエンスグループ

〒100-0003 東京都千代田区一ツ橋一丁目2番2号
TEL: 03-5220-1520
Email: biosupport@summitpharma.co.jp



Inspired by patients.
Driven by science.



抗てんかん剤
ブリーバラセタム錠

薬価基準収載



ブリビアクト® 錠25mg
錠50mg

処方箋医薬品(注意—医師等の処方箋により使用すること)

BRIVIACT®

「効能又は効果」、「用法及び用量」、「禁忌」を含む注意事項等情報等については電子添文をご参照ください。

新発売

製造販売元
ユーシービー・ジャパン株式会社
東京都新宿区西新宿8丁目17番1号

【文献請求先及び問い合わせ先】
ユーシービー・ケアーズ
コンタクトセンター
TEL: 0120-093-189
受付時間 9:00~17:30
(土日・祝日・会社休日を除く)

2024年8月作成 JP-BR-2400085-6

**THE
BRAIN
TUMOUR
CHARITY**

LOOKING FOR FUNDING? WE'RE LOOKING FOR YOU!

We're The Brain Tumour Charity and we're accelerating towards a world where everybody affected by a brain tumour lives a longer, better life.

This means backing researchers who think big and move fast, just like us. Learn more about our support and funding for researchers by scanning the QR code or visiting thebraintumourcharity.org/funding-for-brain-tumour-researchers



© The Brain Tumour Charity 2025. Registered Charity no. 1150054 (England and Wales) SC045081 (Scotland) Company no. 08266522

微量滴下セットスポイトタイプ
20G×95mm / 27G×70mm

*For Microsurgery,
Endoscopic surgery, etc.*

キャップを外した状態
キャップをつけた状態

※画像は20G×95mm

Various application instruments specially designed for

BOLHEAL

スプレーチップ

スプレーセット
目詰まり防止タイプ&スプレーチップ

スプレーセット
(目詰まり防止タイプ)

For Dura mater, etc.

*ボルヒール®組織接着用専用の塗布用器具



血漿分画製剤(生体組織接着剤) 薬価基準収載

ボルヒール®組織接着用

BOLHEAL Tissue Sealant 献血

特定生物由来製品 処方箋医薬品 注意-医師等の処方箋により使用すること

健康にアイデアを
meiji

健康にアイデアを
kmb

効能・効果、用法・用量、禁忌を含む注意事項等情報等については電子添文を参照ください。

製造販売元

KMバイオロジクス株式会社
熊本市北区大湊一丁目6番1号

販売元

Meiji Seika ファルマ株式会社
東京都中央区京橋2-4-16

<文献請求先及び問い合わせ先>

Meiji Seika ファルマ株式会社 くすり相談室
〒104-8002 東京都中央区京橋2-4-16
フリーダイヤル(0120) 093-396
電話(03)3273-3539、FAX(03)3272-2438

2025年4月作成



Next-generation sequencing

臨床研究のための Ion AmpliSeq ターゲットパネル

わずかなDNAやRNAをシンプルなワークフローで解析

Ion AmpliSeq™ テクノロジーは、超高感度なターゲット次世代シーケンシング (NGS) を少量のサンプルで実現します。FFPEやFNAサンプルでも、1 ngのDNAインプットでシーケンスが可能で、単一から数百の遺伝子ターゲットを解析できます。迅速で自動化されたワークフローは、研究者の多様なニーズに対応します。Ion AmpliSeq™ パネルファミリーは、さまざまな研究分野に対応し、オンデマンドで遺伝子パネルをカスタマイズ可能です。



関連セミナー (無料) はこちらからご視聴いただけます
thermofisher.com/jp-ngs-seminar-adv

研究用에만使用できます。診断用には使用いただけません。

© 2025 Thermo Fisher Scientific Inc. All rights reserved.

All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

実際の価格は、弊社販売代理店までお問い合わせください。

価格、製品の仕様、外観、記載内容は予告なしに変更する場合がありますのであらかじめご了承ください。

標準販売条件はこちらをご覧ください。 thermofisher.com/jp-tc ION506-A25040B

サーモフィッシャーサイエンティフィック
ライフテクノロジーズジャパン株式会社

お問い合わせはこちら thermofisher.com/contact

ion torrent

未滅菌

頭蓋骨固定用プレートシステム

サンエープレートシステムⅡ

Saney Plate System II

0.4mmの
ロープロファイルプレート



製造販売元

サンエー精工株式会社

埼玉県朝霞市西弁財1-8-15

TEL.048-483-5779 FAX.048-483-5644

販売名：サンエープレートシステム 医療機器製造販売承認番号：21900BZX00931000

販売名：サンエープレートシステムパワーツール 一般医療機器届出番号：11B1X10002000012

患者様の想いを見つめて、 薬は生まれる。

顕微鏡を覗く日も、薬をお届けする日も、見つめています。

病気とたたかう人の、言葉にできない痛みや不安。生きることへの希望。

私たちは、医師のように普段からお会いすることはできませんが、

そのぶん、患者様の想いにまっすぐ向き合っていたいと思います。

治療を続けるその人を、勇気づける存在であるために。

病気を見つめるだけでなく、想いを見つめて、薬は生まれる。

「ヒューマン・ヘルスケア」。それが、私たちの原点です。

ヒューマン・ヘルスケア企業 エーザイ